The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding

ABSTRACT: Cancer of the endometrium is the most common type of gynecologic cancer in the United States. Vaginal bleeding is the presenting sign in more than 90% of postmenopausal women with endometrial carcinoma. Clinical risk factors for endometrial cancer, including but not limited to age, obesity, use of unopposed estrogen, specific medical comorbidities (e.g., polycystic ovary syndrome, type 2 diabetes mellitus, atypical glandular cells on screening cervical cytology), and family history of gynecologic malignancy also should be considered when evaluating postmenopausal bleeding. The clinical approach to postmenopausal bleeding requires prompt and efficient evaluation to exclude or diagnose endometrial carcinoma and endometrial intraepithelial neoplasia. Transvaginal ultrasonography usually is sufficient for an initial evaluation of postmenopausal bleeding if the ultrasound images reveal a thin endometrial echo (less than or equal to 4 mm), given that an endometrial thickness of 4 mm or less has a greater than 99% negative predictive value for endometrial cancer. Transvaginal ultrasonography is a reasonable alternative to endometrial sampling as a first approach in evaluating a postmenopausal woman with an initial episode of bleeding. If blind sampling does not reveal endometrial hyperplasia or malignancy, further testing, such as hysteroscopy with dilation and curettage, is warranted in the evaluation of women with persistent or recurrent bleeding. An endometrial measurement greater than 4 mm that is incidentally discovered in a postmenopausal patient without bleeding need not routinely trigger evaluation, although an individualized assessment based on patient characteristics and risk factors is appropriate. Transvaginal ultrasonography is not an appropriate screening tool for endometrial cancer in postmenopausal women without bleeding.

Recommendations and Conclusions

The American College of Obstetricians and Gynecologists makes the following recommendations and conclusions:

- The clinical approach to postmenopausal bleeding requires prompt and efficient evaluation to exclude or diagnose endometrial carcinoma and endometrial intraepithelial neoplasia.
- Transvaginal ultrasonography is appropriate for an initial evaluation of postmenopausal bleeding if the ultrasound images reveal a thin endometrial echo (less than or equal to 4 mm), given that an endometrial thickness of 4 mm or less has a greater than 99% negative predictive value for endometrial cancer.
- Transvaginal ultrasonography is a reasonable alternative to endometrial sampling as a first approach in evaluating a postmenopausal woman with an initial episode of bleeding.
- Transvaginal ultrasonography can be useful in the triage of women in whom office endometrial sampling was performed but tissue was insufficient for diagnosis.
- Failure to adequately identify a thin, distinct endometrial echo in a postmenopausal woman with bleeding should trigger sonohysterography, office hysteroscopy, or endometrial sampling.
- If blind sampling does not reveal endometrial hyperplasia or malignancy, further testing, such as
hysteroscopy with dilation and curettage, is warranted in the evaluation of women with persistent or recurrent bleeding.

- An axial uterus, obesity, coexisting myomas, adenomyosis, or previous uterine surgery can contribute to difficulty in obtaining reliable transvaginal ultrasound assessment of endometrial thickness and texture.

- Because rare cases of endometrial carcinoma (particularly type II) can present with an endometrial thickness of less than 3 mm, persistent or recurrent uterine bleeding should prompt a histologic evaluation of the endometrium regardless of endometrial thickness.

- An endometrial measurement greater than 4 mm that is incidentally discovered in a postmenopausal patient without bleeding need not routinely trigger evaluation, although an individualized assessment based on patient characteristics and risk factors is appropriate.

Cancer of the endometrium is the most common type of gynecologic cancer in the United States. In 2017, an estimated 61,380 new cases of uterine cancer were diagnosed and an estimated 10,920 deaths occurred (1). Most cases of uterine cancer (92%) occur in the endometrium and are referred to as endometrial cancer. Vaginal bleeding is the presenting sign in more than 90% of postmenopausal women with endometrial carcinoma (2). Postmenopausal vaginal bleeding usually is caused by atrophic changes of the vagina or endometrium. Depending on age and risk factors, 1–14% of women with postmenopausal bleeding will have endometrial cancer (3–6). The clinical approach to postmenopausal bleeding requires prompt and efficient evaluation to exclude or diagnose endometrial carcinoma and endometrial intraepithelial neoplasia. This Committee Opinion describes the use of transvaginal ultrasonography for the evaluation of women with postmenopausal bleeding as well as the approach to the incidental finding of a thickened endometrial echo in asymptomatic postmenopausal women.

Transvaginal Ultrasonography

Endometrial thickness is measured as the maximum anterior–posterior thickness of the endometrial echo on a long-axis transvaginal view of the uterus. The earliest reports comparing transvaginal ultrasonography with endometrial sampling consistently found that an endometrial thickness of 4–5 mm or less in women with postmenopausal bleeding reliably excluded endometrial cancer (7–9). Since that time, a number of confirmatory multicenter trials have been completed (see Table 1). Transvaginal ultrasonography is appropriate for an initial evaluation of postmenopausal bleeding if the ultrasound images reveal a thin endometrial echo (less than or equal to 4 mm), given that an endometrial thickness of 4 mm or less has a greater than 99% negative predictive value for endometrial cancer.

Table 1. Endometrial Thickness and Cancer Findings in Postmenopausal Women With Bleeding

<table>
<thead>
<tr>
<th>Reference</th>
<th>Endometrial Thickness*</th>
<th>Number of Women With Noted Endometrial Thickness/Total Sample Size</th>
<th>Number of Cases of Cancer</th>
<th>Negative Predictive Value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karlsson 1995‡</td>
<td>≤4 mm</td>
<td>518/1,138</td>
<td>0</td>
<td>100%</td>
</tr>
<tr>
<td>Ferrazzi 1996§</td>
<td>≤4 mm</td>
<td>336/930</td>
<td>2</td>
<td>99.4%</td>
</tr>
<tr>
<td></td>
<td>≤5 mm</td>
<td>456/930</td>
<td>4</td>
<td>99.1%</td>
</tr>
<tr>
<td>Gull 2003¶</td>
<td>≤4 mm</td>
<td>178/339</td>
<td>0</td>
<td>100%</td>
</tr>
<tr>
<td>Wong 2016¶</td>
<td>≤3 mm</td>
<td>1,915/4,383</td>
<td>5</td>
<td>99.7%</td>
</tr>
<tr>
<td></td>
<td>≤4 mm</td>
<td>2,825/4,383</td>
<td>10</td>
<td>99.6%</td>
</tr>
<tr>
<td></td>
<td>≤5 mm</td>
<td>3,131/4,383</td>
<td>11</td>
<td>99.6%</td>
</tr>
</tbody>
</table>

* Determined by transvaginal ultrasonography.

† Negative predictive value: The chance that a negative test result is a true negative.


Ultrasonography to measure endometrial echo should be offered as an initial evaluation only to women with postmenopausal bleeding for whom no further evaluation would be needed if a thin echo is found. Persistent or recurrent bleeding should trigger additional evaluation. Transvaginal ultrasonography is a reasonable alternative to endometrial sampling as a first approach in evaluating a postmenopausal woman with an initial episode of bleeding. Ultrasonography should be used only for patients whose prior probability of cancer and hyperplasia is low enough that no additional testing would be required after a normal ultrasonography. Endometrial sampling also is a reasonable first approach for women with postmenopausal bleeding (10). This initial evaluation does not require performance of both tests.

Clinical risk factors for endometrial cancer, including but not limited to age, obesity, use of unopposed estrogen, specific medical comorbidities (eg, polycystic ovary syndrome, type 2 diabetes mellitus, atypical glandular cells on screening cervical cytology), and family history of gynecologic malignancy also should be considered when evaluating postmenopausal bleeding. A retrospective cohort study of 4,383 women conducted in Hong Kong assessed endometrial cancer detection rates based on different cut-off levels and concluded that the predetermined threshold for further evaluation should be based on available resources, comorbidities, and acceptable detection rates (11). Endometrial sampling should be the first-line test for women with postmenopausal bleeding at higher risk (based on clinical risk factors or clinical presentation) of endometrial cancer and endometrial intraepithelial neoplasia. Table 2 demonstrates the number of cases of endometrial cancer missed by transvaginal ultrasonography based on different thresholds.

Using a 4 mm endometrial echo as a cut-off value, transvaginal ultrasonography has an extremely high negative predictive value (greater than 99%). However, a thickened endometrial echo is not diagnostic of any particular pathology. Even with an extremely high probability that a woman with a negative screening test result truly does not have the condition, a thin endometrial echo does not exclude all possibilities of disease. Furthermore, a thin endometrial echo does not reliably exclude type II endometrial cancer (uterine papillary serous, mucinous, clear cell) (12). Repeated episodes of postmenopausal bleeding and ongoing postmenopausal bleeding require histologic evaluation even in women with an apparent thin endometrial echo (10). Given its ease of performance, outpatient endometrial sampling with disposable devices is the primary method of choice for histologic evaluation. If blind sampling does not reveal endometrial hyperplasia or malignancy, further testing, such as hysteroscopy with dilation and curettage, is warranted in the evaluation of women with persistent or recurrent bleeding (10).

**Table 2. Composite Data on Missed Diagnoses of Endometrial Cancer Based on Different Thresholds of Endometrial Thickness**

<table>
<thead>
<tr>
<th>Threshold of Endometrial Thickness on Transvaginal Ultrasound</th>
<th>Number of Missed Diagnoses of Endometrial Cancer</th>
<th>Equivalent Fraction of Missed Diagnoses in Simplest Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤3 mm</td>
<td>5/1,915 cases of cancer</td>
<td>1 in 383</td>
</tr>
<tr>
<td>≤4 mm</td>
<td>12/4,073 cases of cancer</td>
<td>1 in 339</td>
</tr>
<tr>
<td>≤5 mm</td>
<td>15/3,587 cases of cancer</td>
<td>1 in 239</td>
</tr>
</tbody>
</table>


**Limitations of Transvaginal Ultrasonography**

It is not possible to complete a meaningful transvaginal ultrasound examination with a reliable measurement of endometrial thickness in all women (13–14). The thickest part of the endometrium should be measured perpendicular to its longitudinal plane in the anteroposterior diameter, representing the distance between the echogenic borders (Fig. 1) (15). An axial uterus, obesity, coexisting myomas, adenomyosis, or previous uterine surgery can contribute to difficulty in obtaining reliable transvaginal ultrasound assessment of endometrial thickness and texture. Failure to adequately identify a thin, distinct
endometrial echo in a postmenopausal woman with bleeding should trigger sonohysterography, office hysteroscopy, or endometrial sampling (10). In addition, endometrial fluid, when present, should not be included in measuring endometrial thickness. If an abnormal endometrium is identified, endometrial sampling is warranted.

**Biopsy Findings of Tissue Insufficient for Diagnosis**

Endometrial tissue sampling resulting in findings insufficient for diagnosis is common. In a study of 97 consecutive women with postmenopausal bleeding evaluated by transvaginal ultrasonography and endometrial biopsy, a pipelle biopsy was able to be performed in only 82% of the women (n=45) with an endometrial thickness of less than 5 mm (16). Of these women, a sample adequate for diagnosis was obtained in only 27%. There was no correlation between sample adequacy and parity or cavity length. In a meta-analysis of studies on women with postmenopausal bleeding, the range of sampling failure (eg, inadequate sample or inability to perform the biopsy) with biopsy was 0–54% (17). The associated sample size-weighted failure rate specifically with pipelle biopsy was 10.4% (17).

Transvaginal ultrasonography can be useful in the triage of women in whom office endometrial sampling was performed but tissue was insufficient for diagnosis (18). In one study, 29.8% of women evaluated for abnormal uterine bleeding had an “insufficient endometrial sample” (none of whom had endometrial hyperplasia or cancer after the 2-year follow-up). No further evaluation is necessary after an insufficient endometrial biopsy if subsequent transvaginal ultrasonography demonstrates a thin echo in a woman with postmenopausal bleeding in whom bleeding has ceased (Table 1). Because rare cases of endometrial carcinoma (particularly type II) can present with an endometrial thickness of less than 3 mm, persistent or recurrent uterine bleeding should prompt a histologic evaluation of the endometrium regardless of endometrial thickness (10).

**Postmenopausal Women Without Bleeding**

The utility of transvaginal ultrasonography to exclude pathology in postmenopausal women with bleeding should not be extrapolated to asymptomatic postmenopausal women without bleeding. In 1,750 postmenopausal women without bleeding who were screened for a selective estrogen receptor modulator study, an endometrial thickness of 6 mm or less had a negative predictive value of 99.94% for excluding malignancy (only one case of cancer in 1,750 women) and a 99.77% negative predictive value for complex hyperplasia (only four cases in 1,750 women) (19). Among 42 women with endometrial thickness of greater than 6 mm, there was one case of adenocarcinoma and no cases of hyperplasia (positive predictive value of 2.4%). In another study, 82 asymptomatic postmenopausal women had an incidental ultrasonographic finding of a thick endometrial echo suspected to be a polyp (20). All women underwent...
operative hysteroscopy. Of these women, a benign polyp was found in 68, submucosal myoma in 7, atrophic endometrium in 6, and proliferative endometrium in 1. One polyp contained simple hyperplasia. There were no cases of endometrial carcinoma or complex hyperplasia. The total complication rate was 3.6% (two perforations, one difficult intubation). An asymptomatic population of postmenopausal Danish women who were randomly selected from a civil registry revealed that 13% had a nonbleeding polyp detected by sonohysterography (21).

A retrospective multicenter trial in which 1,152 polyps were removed from asymptomatic postmenopausal women diagnosed by sonohysterography reported one case of stage 1 grade 1 carcinoma (22). The incidence of any cancer in this trial of asymptomatic women was 1 in 288. A retrospective study of 190 postmenopausal women with symptomatic endometrial carcinoma and 123 asymptomatic women with suspicious endometrium detected by transvaginal ultrasonography found no prognostic advantage in terms of 5-year survival between women with cancer discovered incidentally and those treated within 8 weeks of their clinical presentation of postmenopausal bleeding (23).

An endometrial measurement greater than 4 mm that is incidentally discovered in a postmenopausal patient without bleeding need not routinely trigger evaluation, although an individualized assessment based on patient characteristics and risk factors is appropriate. Thus, transvaginal ultrasonography is not an appropriate screening tool for endometrial cancer in postmenopausal women without bleeding.

References